AJR Enterprises LLC
Total Consideration
$110.0M
Purchase-Price Allocation
Goodwill
$35.6M
Assets Acquired
$124.1M
Liabilities Assumed
$10.3M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 4.20% | 4.00% | 3.20% | 2.40% | 2.90% | 2.30% |
| Foreign Rate Differential | 0.00% | 0.00% | 3.70% | 9.30% | 7.70% | — |
| Other Adjustments | 0.20% | 0.80% | -0.10% | 1.80% | 0.90% | — |
| R&D Tax Credits | — | — | — | — | — | — |
| FDII Deduction | — | 0.00% | 0.00% | 0.70% | 0.50% | — |
| SBC (Nondeductible) | 0.00% | — | — | -1.90% | -1.80% | -1.10% |
| Valuation Allowance Change | 0.00% | 0.20% | 0.00% | 0.00% | 0.00% | 0.00% |
| Tax Law Change | — | — | — | — | — | — |
| Qualified Production Activities (Legacy DPAD) | — | — | — | — | — | — |
| Effective Tax Rate | 17.90% | 25.10% | 20.70% | 16.70% | 19.20% | 17.20% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $2.9M | $5.3M | $10.9M | $9.0M | $14.0M | $14.2M |
| Income Taxes Paid (Cash) | $2.5M | $5.9M | $13.2M | $10.6M | $12.8M | $3.6M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$110.0M
Purchase-Price Allocation
Goodwill
$35.6M
Assets Acquired
$124.1M
Liabilities Assumed
$10.3M
Total Consideration
$43.0M
Purchase-Price Allocation
Goodwill
$22.9M
Assets Acquired
$57.6M
Liabilities Assumed
$6.5M
Deferred Tax Liability
$2.3M
Total Consideration
$34.6M
Purchase-Price Allocation
Goodwill
$17.1M
Assets Acquired
$39.6M
Liabilities Assumed
$596.0K
Contingent Earn-Out
—
Total Consideration
$7.5M
Purchase-Price Allocation
Goodwill
$3.2M
Assets Acquired
$7.9M
Liabilities Assumed
$110.0K
Total Consideration
$4.5M
Purchase-Price Allocation
Goodwill
$2.6M
Assets Acquired
$6.4M
Liabilities Assumed
$560.0K
Contingent Earn-Out
$400.0K
Total Consideration
$4.5M
Purchase-Price Allocation
Goodwill
$1.1M
Assets Acquired
$9.3M
Liabilities Assumed
$2.8M
Deferred Tax Liability
$461.0K
Total Consideration
$2.8M
Pro-Forma Combined Entity
Revenue
$610.5M
Net Income
+$69.6M
Diluted EPS
$8.92
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).